Abstract: The invention relates to DNA constructs which are capable of conferring on a plant inducible resistance to a herbicide. The inducible effect may be achieved by using a gene switch such as the alcA/alcR switch derived from A. nidulans. The invention relates in particular to inducible resistance to the herbicide N-phosphonomethyl glycine (glyphosate) and its salts.

Abstract: Optically active 2-substituted tetrahydropyran-4-ols or esters thereof may be prepared using esterases or hydrolases from the corresponding racemic mixtures of esters or alcohols. This provides a route to the corresponding optically active ketones.

Abstract: Crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f][1,4]thiazepine (I) may be prepared by crystallizing 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f][1,4]thiazepine from a non-aromatic solvent such as ethyl acetate, isobutyl acetate, methyl iso-butylketone or methyl tert-butyl ether, preferably in the absence of water. The crystalline material produced may be converted into a pharmaceutically acceptable salt such as a fumarate. The crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f][1,4]thiazepine may be used to treat psychoses.

Abstract: Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.

Abstract: The present invention relates to carbapenems and provides a compound of the formula (I): 1

Abstract: 1 Compounds of formula (I), wherein: n is 1 to 6; Het is a nitrogen containing ring fused to the benzene ring on two adjacent carbon atoms to form a bicyclic ring system which ring system may be optionally substituted; R1 is hydrogen, C1-8alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, aryl, heteroaryl, heterocyclyl, arylC1-6alkyl, heteroarylC1-6alkyl, heterocyclylC1-6alkyl or C3-8cycloalkylC1-6alkyl; R2 is C1-6alkyl, C2-6alkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occurring amino acid; R3 is hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocyclylC1-6alkyl; R4 is hydrogen or C1-6alkyl; or R3 and R4 together with the nitrogen atom to which they are joined form a heterocyclic ring; wherein any group or ring, in R1-R4, is optionally substituted; and pharmceutically acceptable salts and in vivo hydrolysable esters thereof, are described as inhibitors of the production of Tumour Necrosis Factor and/or one or more matrix metal

Abstract: The invention relates to quinazoline derivatives of the formula: [wherein: Y1 represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R8 and R9 each independently represents hydrogen, alkyl or alkoxyalkyl); R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino.

Abstract: A method of protecting a plant against a pathogen is described, the method comprising inducing expression of a plant defensin gene by stimulating the jasmonate and/or ethylenc pathways. Also deseribed is a method of inducing expression of a plant defensin gene, a composition which is capable of inducing expression of a plant defensin gene and a method for screening compounds giving resistance-inducing activity. Preferably, the pathogen is a necrotrophic pathogen.

Abstract: The invention relates to quinazoline derivatives of the formula: 1

Abstract: Compounds of formula I wherein Q1, Q2, Q3, Q4 and Q5 have any of the meanings given in the specification, their N-oxides, and their pharmacuetically acceptable salts are nonpeptide antagonists NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: A compound of formula (I): wherein R1 is hydroxy or of the formula —NHC(═O)(1-4C)alkyl or —NHS(O)n(1-4C)alkyl wherein n is 0, 1 or 2; R2 and R3 are independently hydrogen or fluoro; R4 and R5 are independently hydrogen or methyl; >A—B— is of the formula >C═CH—, or >C(OH)CH2—; >X—Y— is of the formula >C=CH—, or >CHCH2—; and D is S, SO, or SO2; or a pharmaceutically-acceptable salt thereof.

Abstract: A process for the purification of a compound of general formula I: wherein: R1 is hydrogen or C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl (any of which may optionally be substituted with one or more substituents selected from halogen and OH) or COOR4, COR6, CONR4R5 or CONHSO2R4; R4 and R5 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more halogen atoms; R6 is a halogen atom or a group R4; R2 is hydrogen or halo; R3 is C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl, any of which may optionally be substituted with one or more halogen atoms, or halo; or, where appropriate, a salt thereof; from a mixture containing the compound of general formula I together with one or more isomers or di-nitrated analogues thereof; the process comprising dissolving the mixture in a suitable crystallisation solvent and recrystallising the product from the resulting crystallisation solution; characterised in that the crystallisation solution contains not more than 25% loadin

Abstract: The invention provides a gene construct encoding a cell targeting moiety and a heterologous prodrug activating enzyme for use as a medicament in a mammalian host wherein the gene construct is capable of expressing the cell targeting moiety and enzyme as a conjugate within a target cell in the mammalian host and wherein the conjugate is directed to leave the cell thereafter for selective localisation at a cell surface antigen recognised by the cell targeting moiety.

Abstract: Microcapsules of a microcapsule formed of a polyurea shell wall and an encapsulated ingredient or ingredients enclosed within the wall, the wall comprising at least one oligomeric acetal having the moiety in which R is (a) a moiety containing a chain of from 5 to about 40 optionally substituted carbon atoms, (b) a moiety containing a chain of from 4 to about 40 carbon atoms and one or more internally linked oxygen or sulfur atoms or —NH-groups, or (c) an optionally substituted ethylene or propylene moiety Z is (a) an optionally substituted phenyl group, (b) an optionally substituted C1-C20 alkyl, C2-C20 alkenyl, C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, or (c) benzoyl, and n is 1 if R is (a) or (b), or is 2-20 if R is (c).

Abstract: The invention relates to pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor, and their use in the treatment of diabetic complications such as diabetic neuropathy, diabetic retinopathy and diabetic nephropathy.

Abstract: A method for the coloration of a substrate comprising ink jet printing a first and second set of inks onto the substrate wherein: (a) the first set of inks consists of one or more inks each of which independently contains a colorant selected from yellow, magenta, cyan and optionally black; and (b) the second set of inks comprises one or more inks each of which independently contains a dye selected from: a yellow dye of Formula (1) or salt thereof, an orange dye of Formula (2) or salt thereof, a red dye of Formula (3) or salt thereof and a blue dye of Formula (4) or salt thereof, wherein Formulae (1) to (4) are as defined in the description. Also claimed is a set of inks, ink jet printer cartridges, an ink jet printer and substrates printed using the printing method.

Abstract: This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in treating or preventing diseases and medical conditions such as hypercholesterolemia, atherosclerosis and other medical conditions associated with elevated cholesterol levels.

Abstract: Pharmaceutical compositions of 4-(5-cyclopentyloxycarbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide and a gelling agent, in particular hydroxypropylmethylcellulose, are described for treating asthma and related diseases. Processes for the preparation of the compositions are described.

Abstract: A method for the detection of a target nucleic acid, which method comprises contacting template nucleic acid from a sample with (i) a signalling system and (ii) a tailed nucleic acid primer having a template binding region and the tail comprising a linker and a target binding region, in the presence of appropriate nucleoside triphosphates and an agent for polymerization thereof, under conditions such that the template binding region of the primer will hybridize to a complementary sequence in the template nucleic acid and be extended to form a primer extension product, separating any such product from the template whereupon the target binding region in the tail of the primer will hybridize to a sequence in the primer extension product corresponding to the target nucleic acid, and wherein any such target specific hybridization causes a detectable change in the signalling system, such that the presence or absence of the target nucleic acid in the sample is detected by reference to the presence or absence of a de

Abstract: This invention relates to single nucleotide polymorphisms in the LTC4 synthase gene, EMBL accession no. U50136, particularly at one or more of positions 375, 815, 1003, 2169 and 2742. The invention also relates to methods and materials for analyzing allelic variation in the LTC4 synthase gene, and to the use of LTC4 synthase polymorphism in tie diagnosis and treatment of leukotriene mediated diseases such as asthma and allergic rhinitis.